|

BMS-986213 (Relatlimab-Nivolumab FDC) Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: BMS-986016, Relatlimab

Pipeline

Phase 2: 2

Top Sponsors

  • M.D. Anderson Cancer Center2

Indications

  • Cancer2
  • Renal Cell Carcinoma, Clear Cell1
  • Melanoma (Skin)1

Boston, Massachusetts1 trial

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Beth Israel Deaconess Medical Center

Phase 2

Houston, Texas1 trial

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.